M Markman

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. Markman M. Progress in preventing chemotherapy-induced nausea and vomiting. Cleve Clin J Med. 2002;69:609-10, 612, 615-7 pubmed
    ..Prevention and treatment of the delayed and anticipatory forms of chemotherapy-induced emesis remain a challenge. ..
  2. Markman M, Liu P, Wilczynski S, Monk B, Copeland L, Alvarez R, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460-5 pubmed
    ..Twelve cycles of single-agent paclitaxel administered to women with advanced ovarian cancer who attain a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy significantly prolongs the duration of PFS. ..
  3. Markman M, Belinson J, Webster K, Zanotti K, Morrison B, Jacobs B, et al. Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum. Oncology. 2004;66:343-6 pubmed
    ..01). Recombinant human interferon-beta produced a definite biological effect in the serum of treated patients, but this outcome was not translated into any clinically observable or meaningful impact on the disease process. ..
  4. Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am. 2003;17:957-68, viii pubmed